IL314724A - Improved DNA dendrimers and methods of using them - Google Patents

Improved DNA dendrimers and methods of using them

Info

Publication number
IL314724A
IL314724A IL314724A IL31472424A IL314724A IL 314724 A IL314724 A IL 314724A IL 314724 A IL314724 A IL 314724A IL 31472424 A IL31472424 A IL 31472424A IL 314724 A IL314724 A IL 314724A
Authority
IL
Israel
Prior art keywords
methods
enhanced dna
dna dendrimers
dendrimers
enhanced
Prior art date
Application number
IL314724A
Other languages
English (en)
Hebrew (he)
Original Assignee
Code Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Code Biotherapeutics Inc filed Critical Code Biotherapeutics Inc
Publication of IL314724A publication Critical patent/IL314724A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL314724A 2022-02-10 2023-02-09 Improved DNA dendrimers and methods of using them IL314724A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263308776P 2022-02-10 2022-02-10
PCT/US2023/062270 WO2023154788A2 (en) 2022-02-10 2023-02-09 Enhanced dna dendrimers and methods of use thereof

Publications (1)

Publication Number Publication Date
IL314724A true IL314724A (en) 2024-10-01

Family

ID=87565106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314724A IL314724A (en) 2022-02-10 2023-02-09 Improved DNA dendrimers and methods of using them

Country Status (8)

Country Link
US (1) US20230338557A1 (enExample)
EP (1) EP4475891A2 (enExample)
JP (1) JP2025507359A (enExample)
CN (1) CN119095602A (enExample)
AU (1) AU2023217717A1 (enExample)
CA (1) CA3243817A1 (enExample)
IL (1) IL314724A (enExample)
WO (1) WO2023154788A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314724A (en) * 2022-02-10 2024-10-01 Code Biotherapeutics Inc Improved DNA dendrimers and methods of using them
WO2025034978A1 (en) * 2023-08-09 2025-02-13 Code Biotherapeutics, Inc. Enhanced dna dendrimers and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513089A (ja) * 2013-02-01 2016-05-12 ジェニスフィア・エルエルシー 細胞への遺伝子送達のための機能性ｄｎａデンドリマー
US11505821B2 (en) * 2016-08-16 2022-11-22 Touchlight IP Limited Closed linear DNA production
AU2021213927A1 (en) * 2020-01-31 2022-07-28 Tyris Therapeutics, S.L. Closed linear DNA with modified nucleotides
IL314724A (en) * 2022-02-10 2024-10-01 Code Biotherapeutics Inc Improved DNA dendrimers and methods of using them

Also Published As

Publication number Publication date
EP4475891A2 (en) 2024-12-18
WO2023154788A3 (en) 2023-11-09
US20230338557A1 (en) 2023-10-26
CA3243817A1 (en) 2023-08-17
WO2023154788A2 (en) 2023-08-17
CN119095602A (zh) 2024-12-06
JP2025507359A (ja) 2025-03-18
AU2023217717A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
IL297625B2 (en) PI3K-alpha inhibitors and methods of using them
EP4274591A4 (en) ENCAPSULATED RNA POLYNUCLEOTIDES AND METHODS OF USE
IL299925A (en) Compounds of DNA molecules, methods for their preparation and methods of using them
EP4153743A4 (en) EXOSOME-DERIVED PIWI-INTERACTING RNA AND METHODS OF USE THEREOF
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
IL316368A (en) Anti-TL1A antibodies and methods of using them
EP4413147A4 (en) CAPSID VARIANTS AND METHODS OF USE THEREOF
IL314922A (en) Targeted cytokines and methods of using them
IL317643A (en) FCRN binding molecules and methods of using them
SI4200018T1 (sl) Protitelesa proti-PAR-2 in postopki njihove uporabe
EP4274603A4 (en) DNA NUCLEASE-GUIDED TRANSPOSASE COMPOSITIONS AND METHODS OF USE THEREOF
IL299245A (en) LAIR-1 binding agents and methods of using them
IL315845A (en) Anti-dectin-1 antibodies and methods of using them
IL315305A (en) Improved IgG-degrading enzymes and methods of using them
EP4486882A4 (en) MODIFIED NUCLEASES, COMPOSITIONS AND METHODS OF USE THEREOF
GB2613900B (en) Novel compounds and methods of use thereof
EP4308097A4 (en) NON-HYDROXAMATE HDAC6 INHIBITORS AND METHODS OF USE THEREOF
IL318277A (en) Encoded RNA and methods for using it
IL317690A (en) Anti-GPNMB antibodies and methods of using them
IL318694A (en) Antibodies against CCR8 and methods of using them
IL327476A (en) Modified oligonucleotides and methods for using them
EP4423138A4 (en) Anti-CD47 antibodies and methods for using them
GB202119051D0 (en) Wingsail and method of use
ZA202210033B (en) Apparatus for improved transfection efficiency and/or protein expression and method of use thereof